Chaumont, H. http://orcid.org/0000-0002-1585-7512
San-Galli, A.
Martino, F.
Couratier, C.
Joguet, G.
Carles, M.
Roze, E.
Lannuzel, A.
Article History
Received: 3 June 2020
Revised: 5 June 2020
Accepted: 8 June 2020
First Online: 12 June 2020
Compliance with ethical standards
:
: Not applicable.
: Not applicable.
: Patient’s consent has been obtained.
: Dr. Chaumont reports having received travel grant from PEPS development, Roche and Pfizer. Dr. Roze reports served on scientific advisory boards for Orkyn, Aguettant, Merz-Pharma; received honoraria for speeches from Orkyn, Aguettant, Merz-Pharma, Medday-Pharma, Everpharma, International Parkinson and Movement disorders Society; received research support from Merz-Pharma, Orkyn, Aguettant, Elivie, Ipsen, Everpharma, Fondation Desmarest, AMADYS, Fonds de Dotation Brou de Laurière, Agence Nationale de la Recherche; received travel grant from Vitalair, PEPS development, Aguettant, Merz-Pharma, Ipsen, Merck, Orkyn, Elivie, Adelia Medical, Dystonia Medical Research Foundation, International Parkinson and Movement disorders Society, European Academy of Neurology, International Association of Parkinsonism and Related Disorders. Dr. Couratier reports having received travel grant from Allergan, Novartis, Esai, UCB, Medtronic, Merck Serono, Biogen, LFB, Teva, Icomed, GSK, Genzyme, Aguettant, Cyberonics and Merz-Pharma. Dr. Lannuzel reports having received research support from France Parkinson, PSP France, Agence Nationale de la Recherche, Fonds Européen de DEveloppement Regional, French Ministry of Health, University Hospital of Guadeloupe, received honoraria for a speech from Association des Neurologues du Québec; received travel grant from Vitalair, PEPS development, Merz-Pharma, International Parkinson and Movement disorders Society. Dr. San-Galli, Dr. Martino, Dr. Carles, and Dr. Joguet report no disclosures.
: Not applicable.
: Not applicable.
Free to read: This content has been made available to all.